Immunomodulatory effects of blood transfusions: The synergic role of soluble HLA Class I free heavy-chain molecules detectable in blood components

Transfusion

Volumn 48, Issue 8, 2008, Pages 1591-1597

  Ghio, Massimo ^a   Contini, Paola ^b   Ubezio, Gianluca ^b   Mazzei, Clemente ^b   Puppo, Franco ^b   Indiveri, Franco ^b  

^a UNIVERSITY OF GENOA   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; FAS LIGAND; HLA ANTIGEN CLASS 1; INTERLEUKIN 2;

APOPTOSIS; ARTICLE; BLOOD COMPONENT; BLOOD DONOR; BLOOD TRANSFUSION; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME IMMUNOASSAY; EPSTEIN BARR VIRUS; HUMAN; HUMAN CELL; IMMUNOMODULATION; PROTEIN PROTEIN INTERACTION; THROMBOCYTE; WESTERN BLOTTING;

ANTIGENS, CD95; APOPTOSIS; BETA 2-MICROGLOBULIN; BLOOD PRESERVATION; BLOOD TRANSFUSION; BLOOD TRANSFUSION, AUTOLOGOUS; EPSTEIN-BARR VIRUS INFECTIONS; FAS LIGAND PROTEIN; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSION; INTERLEUKIN-2; ISOANTIGENS; RNA, MESSENGER; SOLUBILITY; T-LYMPHOCYTES, CYTOTOXIC;

EID: 48249114040     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/j.1537-2995.2008.01720.x     Document Type: Article

References (39)

1. Billingham RE, Brent L, Medawar PB Actively acquired tolerance" of foreign cells. Nature 1953 172 : 603 6.
2. Opelz G, Mickey MR, Terasaki P. Effect of blood transfusions on subsequent kidney transplants. Transplant Proc 1973 5 : 253 9.
3. Persijn GG, Cohen B, Lansbergen Q, Van Rood JJ. Retrospective and prospective studies on the effect of blood transfusions in renal transplantation in The Netherlands. Transplantation 1979 28 : 396 401.
4. Jonker M, Persijn GG, Parlevliet J, Frederiks E, Van Rood JJ. The influence of previous immunization on skin graft survival. Transplantation 1979 27 : 250 3.
5. Dzik S, Blajchman MA, Blumberg N, Kirkley SA, Heal JM, Wood K. Current research on the immunomodulatory effect of allogeneic blood transfusion. Vox Sang 1996 70 : 187 94.
6. Jonker M, Persijn GG, Parlevliet J, Frederiks E, Van Rood JJ. The influence of previous immunization on skin graft survival. Transplantation 1979 27 : 250 3.
7. Blajchman MA. Transfusion immunomodulation or TRIM: what does it mean clinically Hematology 2005 10 (Suppl 1 208 14.
8. Vamvakas EC. Deleterious clinical effects of transfusion immunomodulation: proven beyond a reasonable doubt. Transfusion 2006 46 : 492 4.
9. Blumberg N. Deleterious clinical effects of transfusion immunomodulation: proven beyond a reasonable doubt. Transfusion 2005 45 (2 Suppl 33S 39S.
10. Rogers MA, Blumberg N, Saint SK, Kim C, Nallamothu BK, Langa KM. Allogeneic blood transfusions explain increased mortality in women after coronary artery bypass graft surgery. Am Heart J 2006 152 : 1028 34.
11. Ghio M, Contini P, Mazzei C, Merlo A, Filaci G, Setti M, Indiveri F, Puppo F. In vitro immunosuppressive activity of soluble HLA class I and Fas ligand molecules: do they play a role in autologous blood transfusion? Transfusion 2001 41 : 988 96.
12. Puppo F, Ghio M, Contini P, Mazzei C, Indiveri F. Fas, Fas ligand, and transfusion immunomodulation. Transfusion 2001 41 : 416 8.
13. Ghio M, Contini P, Mazzei C, Brenci S, Barberis G, Filaci G, Indiveri F, Puppo F. Soluble HLA class I, HLA class II, and Fas ligand in blood components: a possible key to explain the immunomodulatory effects of allogeneic blood transfusions. Blood 1999 93 : 1770 7.
14. Ottonello L, Ghio M, Contini P, Bertolotto M, Bianchi G, Montecucco F, Colonna M, Mazzei C, Dallegri F, Indiveri F. Nonleukoreduced red blood cell transfusion induces a sustained inhibition of neutrophil chemotaxis by stimulating in vivo production of transforming growth factor-beta1 by neutrophils: role of the immunoglobulinlike transcript 1, sFasL, and sHLA-I. Transfusion 2007 47 : 1395 404.
15. Ghio M, Ottonello L, Contini P, Amelotti M, Mazzei C, Indiveri F, Puppo F, Dallegri F. Transforming growth factor-beta1 in supernatants from stored red blood cells inhibits neutrophil locomotion. Blood 2003 102 : 1100 7.
16. Dobbe LM, Stam NJ, Neefjes JJ, Giphart MJ. Biochemical complexity of serum HLA Class I molecules. Immunogenetics 1988 27 : 203 10.
17. Demaria S, Schwab R, Bushkin Y. The origin and fate of β2-m-free MHC Class I molecules induced on activated T cells. Cell Immunol 1992 142 : 103 13.
18. Neefjes JJ, Smit L, Gehrmann M, Ploegh HL. The fate of the three subunits of major histocompatibility complex Class I molecules. Eur J Immunol 1992 22 : 1609 14.
19. Pickl WF, Majdic O, Faé I, Reuschel R, Holter W, Knapp W. The soluble pool of β2-microglobulin free HLA Class I α-chains. J Immunol 1993 151 : 2613 22.
20. Allison JP, Pellegrino MA, Ferrone S, Callahan GN, Reisfeld RA. Biologic and chemical characterization of HLA antigens in human serum. J Immunol 1977 118 : 1004 9.
21. Krangel MS. Secretion of HLA-A and -B antigens via an alternative RNA splicing pathway. J Exp Med 1986 163 : 1173 90.
22. Krangel MS. Two forms of HLA Class I molecules in human plasma. Hum Immunol 1987 20 : 155 65.
23. Ploegh HL, Cannon LE, Strominger JL. Cell-free translation of the mRNAs for the heavy and light chains of HLA-A and HLA-B antigens. Proc Natl Acad Sci U S A 1979 76 : 2273 7.
24. Demaria S, Schwab R, Gottesman SR, Bushkin Y. Soluble β2-microglobulin-free Class I heavy chains are released from the surface of activated and leukemia cells by a metallo protease. J Biol Chem 1994 269 : 6689 94.
25. Barnstable CJ, Bodmer WF, Brown G, Galfre G, Milstein C, Williams AF, Ziegler AZ. Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens: new tools for genetic analysis. Cell 1978 14 : 9.
26. Desai SA, Wang X, Noronha EJ, Zhou Q, Rebmann V, Grosse-Wilde H, Moy FJ, Powers R, Ferrone S. Structural relatedness of distinct determinants recognized by monoclonal antibody TP25.99 on beta 2-microglobulin-associated and beta 2-microglobulin-free HLA class I heavy chains. J Immunol 2000 165 : 3275 83.
27. D'Urso CM, Wang ZG, Cao Y, Tatake R, Zeff RA, Ferrone S. Lack of HLA class I antigen expression by cultured melanoma cells FO-1 due to a defect in B2m gene expression. J Clin Invest 1991 87 : 284.
28. Pellegrino MA, Ng AK, Russo C, Ferrone S. Heterogeneous distribution of determinants defined by monoclonal antibodies on HLA-A and B antigens bearing molecules. Transplantation 1982 34 : 18.
29. Gavioli R, de Campos-Lima PO, Kurilla MG, Kieff E, Klein G, Masucci MG. Recognition of the Epstein-Barr virus-encoded nuclear antigens EBNA-4 and EBNA-6 by HLA-A11-restricted cytotoxic T lymphocytes: implication for down-regulation of HLA-A11 in Burkitt lymphoma. Proc Natl Acad Sci U S A 1992 89 : 5862 6.
30. Puppo F, Bignardi D, Contini P, Hamby CV, Brenci S, Lanza L, Ghio M, Scudeletti M, Indiveri F, Ferrone S. Beta2-micro-free HLA class I heavy chain levels in sera of healthy individuals. Lack of association with beta2-microglobulin-associated HLA class I heavy chain levels and HLA phenotype. Tissue Antigens 1999 53 : 253 62.
31. Puppo F, Contini P, Ghio M, Brenci S, Scudeletti M, Filaci G, Ferrone S, Indiveri F. Soluble human MHC class I molecules induce soluble Fas ligand secretion and trigger apoptosis in activated CD8(+) Fas (CD95)(+) T lymphocytes. Int Immunol 2000 12 : 195 203.
32. Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W, editors. Current protocols in immunology. New York : John Wiley & Sons 2003. p. 8.2.5.
33. Contini P, Ghio M, Merlo A, Poggi A, Indiveri F, Puppo F. Apoptosis of antigen-specific T lymphocytes upon the engagement of CD8 by soluble HLA class I molecules is Fas ligand/Fas mediated: evidence for the involvement of p56lck, calcium calmodulin kinase II, and calcium-independent protein kinase C signaling pathways and for NF-kappaB and NF-AT nuclear translocation. J Immunol 2005 175 : 7244 54.
34. Davenport MP, Smith KJ, Barouch D, Reid SW, Bodnar WM, Willis AC, Hunt DF, Hill AV. HLA class I binding motifs derived from random peptide libraries differ at the COOH terminus from those of eluted peptides. J Exp Med 1997 185 : 367 71.
35. Ren D, Wang F, He X, Jiang L, Li D, Ying H, Sun S. Construction of bioactive chimeric MHC class I tetramer by expression and purification of human-murine chimeric MHC heavy chain and beta (2) μ as a fusion protein in Escherichia coli. Protein Expr Purif 2006 50 : 171 8.
36. Tanigaki N. The specificity and efficiency of endogenous peptides in the induction of HLA class I alpha chain refolding. Eur J Immunol 1992 22 : 2177 80.
37. Vamvakas EC. Possible mechanisms of allogeneic blood transfusion- associated postoperative infection. Transfus Med Rev 2002 16 : 144 60.
38. Vamvakas EC. Pneumonia as a complication of blood product transfusion in the critically ill: transfusion-related immunomodulation (TRIM). Crit Care Med 2006 34 (5 Suppl S151 9.
39. Raghavan M, Marik PE. Anemia, allogenic blood transfusion, and immunomodulation in the critically ill. Chest 2005 127 : 295 307.